Inhibition of c-Abl with imatinib mesylate, an anti-CML drug, or ablation of c-Abl using Prx1-Cre, which marks smooth muscle cells, recapitulated most of the muscularis propria phenotypes. Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.